Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao

被引:4
作者
Ng, Hoi Man [1 ]
Lei, Chon Lok [2 ]
Fu, Siyi [2 ]
Li, Enqin [2 ]
Leong, Sek In [1 ]
Nip, Chu Iong [1 ]
Choi, Nga Man [1 ]
Lai, Kai Seng [1 ]
Tang, Xi Jun [3 ]
Lei, Chon Leng [1 ]
Xu, Ren-He [2 ]
机构
[1] Kiang Wu Hosp, Lab Dept, Macau, Peoples R China
[2] Univ Macau, Fac Hlth Sci, Macau, Peoples R China
[3] Zhuhai Hosp Combined Tradit Chinese & Western Med, Lab Dept, Zhuhai, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
SARS-CoV-2; inactivated vaccine; mRNA vaccine; heterologous vaccinations; antibodies; spike proteins; nucleocapsid proteins; Macao;
D O I
10.3389/fimmu.2023.1131985
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mRNA vaccines (RVs) can reduce the severity and mortality of severe acute respiratory syndrome coronavirus (SARS-CoV-2). However, almost only the inactivated vaccines (IVs) but no RVs had been used in mainland China until most recently, and the relaxing of its anti-pandemic strategies in December 2022 increased concerns about new outbreaks. In comparison, many of the citizens in Macao Special Administrative Region of China received three doses of IV (3IV) or RV (3RV), or 2 doses of IV plus one booster of RV (2IV+1RV). By the end of 2022, we recruited 147 participants with various vaccinations in Macao and detected antibodies (Abs) against the spike (S) protein and nucleocapsid (N) protein of the virus as well as neutralizing antibodies (NAb) in their serum. We observed that the level of anti-S Ab or NAb was similarly high with both 3RV and 2IV+1RV but lower with 3IV. In contrast, the level of anti-N Ab was the highest with 3IV like that in convalescents, intermediate with 2IV+1RV, and the lowest with 3RV. Whereas no significant differences in the basal levels of cytokines related to T-cell activation were observed among the various vaccination groups before and after the boosters. No vaccinees reported severe adverse events. Since Macao took one of the most stringent non-pharmaceutical interventions in the world, this study possesses much higher confidence in the vaccination results than many other studies from highly infected regions. Our findings suggest that the heterologous vaccination 2IV+1RV outperforms the homologous vaccinations 3IV and 3RV as it induces not only anti-S Ab (to the level as with 3RV) but also anti-N antibodies (via the IV). It combines the advantages of both RV (to block the viral entry) and IV (to also intervene the subsequent pathological processes such as intracellular viral replication and interference with the signal transduction and hence the biological functions of host cells).
引用
收藏
页数:7
相关论文
共 50 条
[31]   Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models [J].
Mazunina, Elena P. ;
Gushchin, Vladimir A. ;
Bykonia, Evgeniia N. ;
Kleymenov, Denis A. ;
Siniavin, Andrei E. ;
Kozlova, Sofia R. ;
Mukasheva, Evgenya A. ;
Shidlovskaya, Elena V. ;
Kuznetsova, Nadezhda A. ;
Usachev, Evgeny V. ;
Zlobin, Vladimir I. ;
Burtseva, Elena I. ;
Ivanov, Roman A. ;
Logunov, Denis Y. ;
Gintsburg, Alexander L. .
VACCINES, 2024, 12 (11)
[32]   Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools [J].
da Silva, Maria Karolaynne ;
de Oliveira Campos, Daniel Melo ;
Akash, Shopnil ;
Akter, Shahina ;
Yee, Leow Chiuan ;
Fulco, Umberto Laino ;
Nobre Oliveira, Jonas Ivan .
VIRUSES-BASEL, 2023, 15 (10)
[33]   Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study [J].
Jara, Alejandro ;
Undurraga, Eduardo A. ;
Flores, Juan Carlos ;
Zubizarreta, Jose R. ;
Gonzalez, Cecilia ;
Pizarro, Alejandra ;
Ortuno-Borroto, Duniel ;
Acevedo, Johanna ;
Leo, Katherinne ;
Paredes, Fabio ;
Bralic, Tomas ;
Vergara, Veronica ;
Leon, Francisco ;
Parot, Ignacio ;
Leighton, Paulina ;
Suarez, Pamela ;
Rios, Juan Carlos ;
Garcia-Escorza, Heriberto ;
Araos, Rafael .
LANCET REGIONAL HEALTH-AMERICAS, 2023, 21
[34]   The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults [J].
Wang, Qinjin ;
Ning, Jie ;
Chen, Ying ;
Li, Bin ;
Shi, Liang ;
He, Taojun ;
Zhang, Fang ;
Chen, Xingchi ;
Zhai, Aixia ;
Wu, Chao .
FRONTIERS IN MICROBIOLOGY, 2022, 13
[35]   Evaluation of the Effect of mRNA and Inactivated SARS-CoV-2 Vaccines on the Levels of Cytokines IL-2, IFN-γ, and Anti-RBD Spike SARS-CoV-2 Antibodies in People Living with HIV (PLHIV) [J].
Amanah, Amanah ;
Ariyanto, Ibnu Agus ;
Bela, Budiman ;
Primanagara, Risnandya ;
Sudarmono, Pratiwi .
BIOMEDICINES, 2024, 12 (09)
[36]   Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants [J].
Montgomerie, Isabelle ;
Bird, Thomas W. ;
Palmer, Olga R. ;
Mason, Ngarangi C. ;
Pankhurst, Theresa E. ;
Lawley, Blair ;
Hernandez, Leonor C. ;
Harfoot, Rhodri ;
Authier-Hall, Astrid ;
Anderson, Danielle E. ;
Hilligan, Kerry L. ;
Buick, Kaitlin H. ;
Mbenza, Naasson M. ;
Mittelstadt, Gerd ;
Maxwell, Samara ;
Sinha, Shubhra ;
Kuang, Joanna ;
Subbarao, Kanta ;
Parker, Emily J. ;
Sher, Alan ;
Hermans, Ian F. ;
Ussher, James E. ;
Quinones-Mateu, Miguel E. ;
Comoletti, Davide ;
Connor, Lisa M. .
ISCIENCE, 2023, 26 (04)
[37]   Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection [J].
Olukitibi, Titus A. ;
Ao, Zhujun ;
Warner, Bryce ;
Unat, Rodrigo ;
Kobasa, Darwyn ;
Yao, Xiaojian .
VACCINES, 2023, 11 (03)
[38]   Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant [J].
Lyke, Kirsten E. ;
Atmar, Robert L. ;
Islas, Clara Dominguez ;
Posavad, Christine M. ;
Szydlo, Daniel ;
Chourdhury, Rahul Paul ;
Deming, Meagan E. ;
Eaton, Amanda ;
Jackson, Lisa A. ;
Branche, Angela R. ;
Sahly, Hana M. El ;
Rostad, Christina A. ;
Martin, Judith M. ;
Johnston, Christine ;
Rupp, Richard E. ;
Mulligan, Mark J. ;
Brady, Rebecca C. ;
Frenck, Robert W., Jr. ;
Backer, Martin ;
Kottkamp, Angelica C. ;
Babu, Tara M. ;
Rajakumar, Kumaravel ;
Edupuganti, Srilatha ;
Dobrzynski, David ;
Coler, Rhea N. ;
Archer, Janet I. ;
Crandon, Sonja ;
Zemanek, Jillian A. ;
Brown, Elizabeth R. ;
Neuzil, Kathleen M. ;
Stephens, David S. ;
Post, Diane J. ;
Nayak, Seema U. ;
Suthar, Mehul S. ;
Roberts, Paul C. ;
Beigel, John H. ;
Montefiori, David C. ;
DMID Std Grp .
CELL REPORTS MEDICINE, 2022, 3 (07)
[39]   The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies [J].
Papageorgiou, Anastassios C. ;
Mohsin, Imran .
CELLS, 2020, 9 (11) :1-16
[40]   Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population [J].
Intapiboon, Porntip ;
Seepathomnarong, Purilap ;
Ongarj, Jomkwan ;
Surasombatpattana, Smonrapat ;
Uppanisakorn, Supattra ;
Mahasirimongkol, Surakameth ;
Sawaengdee, Waritta ;
Phumiamorn, Supaporn ;
Sapsutthipas, Sompong ;
Sangsupawanich, Pasuree ;
Chusri, Sarunyou ;
Pinpathomrat, Nawamin .
VACCINES, 2021, 9 (12)